Name | Title | Contact Details |
---|---|---|
Chris Tulumba |
Deputy CISO / Director Information Security | Profile |
Cynapsus Therapeutics Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ortho Clinical Diagnostics is an in vitro diagnostics company that makes products and diagnostic equipment for blood testing.
Sano Informed Prescribing, Inc. is creating game-changing personal and population health management capabilities, previously unattainable in the healthcare market, by revolutionizing medication therapy through the fast, clinically precise detection of medications in patients. The vision of Sano Informed Prescribing is to improve individual and population health; enable healthcare professionals to evaluate, adjust and implement best possible medication therapy programs; and reduce the costs associated with quality healthcare. Sano Informed Prescribing’s mission is to ensure that every patient receives the most effective drug therapy possible. We will do this by providing precise, patient-specific medication analyses that empower healthcare professionals to tailor care; achieve optimal patient health outcomes and satisfaction; and impact overall healthcare costs.
Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.